RxDoctor Payments Data

Peggy Avina, MD

Family Medicine · Elfrida, AZNPI 1558362145

Payments from drug & device makers

$1,310in general payments, 2019–2025

Across 36 payments — averaging $36.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$522
  • Viiv Healthcare Company$251
  • Organogenesis Inc.$125
  • Merck$98
  • AbbVie$97
  • Amgen$95
  • plus $122 from 3 others

What the payments were for

  • Food & beverage$1,310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,310 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$3,313
Medicare patients
18
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala63$307,046
JulucaDolutegravir/Rilpivirine53$189,875
GenvoyaElviteg/Cob/Emtri/Tenof Alafen39$150,013
FarxigaDapagliflozin Propanediol101$86,501
TivicayDolutegravir Sodium37$85,600
OdefseyEmtricitab/Rilpiviri/Tenof Ala21$74,106
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$69,429
OzempicSemaglutide50$51,301
PrezcobixDarunavir/Cobicistat19$48,970
DovatoDolutegravir Sodium/Lamivudine14$45,726
XareltoRivaroxaban16$20,168
JanuviaSitagliptin Phosphate33$19,712
EliquisApixaban20$17,786
MounjaroTirzepatide15$15,445
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Tivicay, Dovato$251$321,201104 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$522$112,067159 claims
MerckJanuvia, Belsomra, Dulera$98$28,82158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Elfrida

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →